575
Participants
Start Date
May 23, 2023
Primary Completion Date
April 1, 2027
Study Completion Date
August 31, 2027
FOG-001
FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days
mFOLFOX-6
mFOLFOX-6 will be administered per the prescribing information in combination with FOG-001
Nivolumab
Nivolumab will be administered per the prescribing information in combination with FOG-001
Trifluridine/tipiracil
Trifluridine/tipiracil will be administered per the prescribing information in combination with FOG-001
Bevacizumab
Bevacizumab will be administered per the prescribing information in combination with FOG-001
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
RECRUITING
Johns Hopkins University, Sibley Memorial Hospital, Washington D.C.
RECRUITING
Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
RECRUITING
Florida Cancer Specialists, Lake Mary
RECRUITING
Sarah Cannon Research Institute, Nashville
RECRUITING
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
RECRUITING
University of Wisconsin, Carbone Cancer Center, Madison
RECRUITING
Washington University School of Medicine, St Louis
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
South Texas Accelerated Research Therapeutics, LLC, San Antonio
RECRUITING
Honor Health, Scottsdale
RECRUITING
Stanford Cancer Institute, Stanford University, Palo Alto
RECRUITING
Oregon Health and Science University, Portland
RECRUITING
Yale University School of Medicine, New Haven
RECRUITING
Massachusetts General Hospital, Boston
Lead Sponsor
Parabilis Medicines, Inc.
INDUSTRY